ahead cc sale growth ep beat
report revenu y/i constant currenc
driven strength core breast health busi cc intern sale
cc vs est street organ basi ex blood
screen cynosur cyno sale increas y/i gross margin declin
yoy due geograph product mix oper margin
declin y/i cyno non-gaap ep in-lin w/street
sale beat filter bottom-lin despit soft margin
took impair charg goodwil in-process
cyno longer expect meet origin deal expect time
cut revenu guid report cc
lsd organ vs prior howev despit sale cut ep
maintain expect off-set short fall delay
increment invest realloc tax save skeptic
cyno sinc deal upgrad earli link core busi solid
assum prematur cyno bottom would benefit easier
comp well upgrad sale forc given attract fundament
medic aesthet market appar chang sale forc
take longer expect gain traction rebound take longer
expect cyno miscalcul like put management difficult state
share like trade sharpli news howev reiter buy rate
sum-of-the-part analysi suggest core busi worth
cyno still remain call option bar would final low
enough beat
lower estim cyno po
lower sale estim ep
new po base
ep estim prior in-lin compani four-year histor averag
net dbt
review core intact cyno
 get write-down
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
compani acquir cynosur lead
medic aesthet compani larg portfolio
laser-bas product
core mammographi
diagnost busi perform better
expect especi ou market help
off-set concern surpris cynosur
acquisit done hide slow growth
continu reserv
cynosur believ expect like
bottom point call
option view better expect result
cynosur could help close valuat gap
dx peer
po base approxim calendar ep estim impli
ev/ebitda in-line three-year histor averag
discount compani dx/medtech peer multipl
upsid risk po better-than-expect synergi cynosur
acquisit unreal benefit chang tax code faster growth
core diagnost mammographi gynecolog surgeri end market
ynosur competit pressur slower uptak reimburs new product
unfavor chang clinic practic guidelin manag departur regulatori
risk faster declin legaci busi
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
